Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 301 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parathyroid Clear all
Completed Phase 4 Interventional Results available

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

NCT00823303
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Paricalcitol, Calcitriol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 8, 2026, 5:42 PM EDT
Completed No phase listed Observational

Optional Sub-study to Intraoperative Imaging With ICG Registry

NCT02651246
View directory record Official record
Conditions
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Interventions
data collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 8, 2026, 5:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study

NCT00105274
View directory record Official record
Conditions
DiGeorge Syndrome, Velocardiofacial Syndrome, 22q11.2 Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Phase 1Phase 2 Interventional

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

NCT03977662
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Co-transplantation of PTG with pancreatic islets
Combination Product
Lead sponsor
Peter Stock
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Phase 4 Interventional Results available

A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism

NCT02910466
View directory record Official record
Conditions
Chronic Hypoparathyroidism, Hypoparathyroidism
Interventions
rhPTH(1-84)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Not applicable Interventional Results available

Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

NCT05022641
View directory record Official record
Conditions
Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism
Interventions
PTeye, Standard of Care
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Not applicable Interventional Results available

Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas

NCT01574287
View directory record Official record
Conditions
Parathyroid Disease
Interventions
FACBC
Drug
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

NCT00417612
View directory record Official record
Conditions
Hypophosphatemia, Familial, Hyperparathyroidism
Interventions
Paricalcitol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
9 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions

NCT00601328
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Hypocalcemia
Interventions
Calcitriol
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhancing Skeletal Adaptations to PTH and Exercise

NCT05029128
View directory record Official record
Conditions
Exercise, Bone Resorption, Bone Formation
Interventions
Endurance exercise intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
25 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)

NCT05149898
View directory record Official record
Conditions
22Q11.2 Deletion Syndrome
Interventions
ZYN002
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 8, 2026, 5:42 PM EDT
Withdrawn Not applicable Interventional

The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

NCT00347737
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Leland Graves III, MD
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Phase 4 Interventional

A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis

NCT00454350
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol (doxercalciferol injection), Zemplar (Paricalcitol injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 8, 2026, 5:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Metabolism and Parathyroid Hormone-related Protein (PTHrP) Lactation Study

NCT00430417
View directory record Official record
Conditions
Bone Diseases, Endocrine
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

NCT00975000
View directory record Official record
Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 8, 2026, 5:42 PM EDT
Recruiting Phase 4 Interventional

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

NCT03935984
View directory record Official record
Conditions
Primary Hyperparathyroidism, Hypercalcemia
Interventions
Calcitonin
Drug
Lead sponsor
Joseph Sferra
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 8, 2026, 5:42 PM EDT
Recruiting Phase 3 Interventional

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 8, 2026, 5:42 PM EDT
Recruiting No phase listed Observational

Comprehensive Data Collection and Follow-Up for Patients With Thyroid, Parathyroid and Adrenal Disease

NCT03050762
View directory record Official record
Conditions
Endocrine Disease
Interventions
Data Collection, Follow Up
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Not applicable Interventional Results available

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.

NCT04281875
View directory record Official record
Conditions
Postoperative Hypoparathyroidism, Thyroid Neoplasms, Thyroid Cancer
Interventions
NIRAF Detection Technology
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 8, 2026, 5:42 PM EDT
Completed No phase listed Observational

Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes

NCT00004351
View directory record Official record
Conditions
Williams Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Shprintzen Syndrome, Smith-Magenis Syndrome, DiGeorge Syndrome, Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
0 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

NCT00261950
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Sensipar (Cinacalcet HCl)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

NCT00005005
View directory record Official record
Conditions
Osteoporosis
Interventions
PTH, Alendronate
Drug
Lead sponsor
Dennis Black
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
4
States / cities
Bangor, Maine • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

NCT01191762
View directory record Official record
Conditions
Hyperparathyroidism, Chronic Kidney Disease
Interventions
sevelamer carbonate, placebo
Drug
Lead sponsor
Kenneth R. Phelps, M.D.
Individual
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 8, 2026, 5:42 PM EDT
Completed Not applicable Interventional Results available

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

NCT00785629
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Calcium acetate, Lanthanum Carbonate, Sevelamer Carbonate, Placebo
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Sep 8, 2026, 5:42 PM EDT